Source: ClinicaSpace

RadiaDyn: RadiaDyne Announces First Commercial Sale Milestone of Their OARtrac Patient Dose Monitoring System to Leading Cancer Center

OARtrac provides critical radiation dose feedback which helps facilitate adaptive radiotherapy for true personalized treatment with the goal to reduce side effects and offer better clinical outcomes.

Read full article »
Est. Annual Revenue
$25-100M
Est. Employees
100-250
John Isham's photo - Founder & CEO of RadiaDyn

Founder & CEO

John Isham

CEO Approval Rating

81/100

Read more